Microbot Medical closes $25.2 million preferred-option exercise tranche
Microbot Medical completed the first closing of preferred investment-option exercises for approximately $25.2 million in gross proceeds, a public-company capital-markets transaction rather than a private funding round.
Evidence notes
- The first closing generated approximately USD 25,200,000 in gross proceeds.
- The transaction involved exercise of outstanding preferred investment options.
- Microbot Medical completed the first closing of preferred investment-option exercises for approximately $25.2 million in gross proceeds, a public-company capital-markets transaction rather than a private funding round.
Company context
Microbot Medical develops LIBERTY, a compact single-use endovascular robotic system designed for remotely operated vascular access and navigation.